Replimune Group, Inc. (NASDAQ:REPL) Shares Purchased by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC increased its stake in shares of Replimune Group, Inc. (NASDAQ:REPL) by 282.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 72,207 shares of the company’s stock after acquiring an additional 53,313 shares during the quarter. Cubist Systematic Strategies LLC owned about 0.11% of Replimune Group worth $650,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Nisa Investment Advisors LLC raised its stake in Replimune Group by 10,304.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock worth $45,000 after acquiring an additional 4,946 shares in the last quarter. Point72 DIFC Ltd acquired a new stake in Replimune Group during the 2nd quarter worth $57,000. Diversified Trust Co acquired a new position in Replimune Group in the first quarter valued at $94,000. China Universal Asset Management Co. Ltd. increased its stake in Replimune Group by 72.8% in the first quarter. China Universal Asset Management Co. Ltd. now owns 11,808 shares of the company’s stock valued at $96,000 after purchasing an additional 4,975 shares during the period. Finally, Arizona State Retirement System acquired a new position in Replimune Group in the second quarter valued at $108,000. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CFO Emily Luisa Hill sold 8,938 shares of the business’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $10.18, for a total transaction of $90,988.84. Following the sale, the chief financial officer now owns 101,057 shares of the company’s stock, valued at approximately $1,028,760.26. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 8.80% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research analysts have commented on REPL shares. Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. HC Wainwright restated a “buy” rating and issued a $17.00 price objective on shares of Replimune Group in a research note on Monday, September 16th. JPMorgan Chase & Co. lifted their price objective on shares of Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, September 24th. Finally, Roth Mkm started coverage on shares of Replimune Group in a report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 target price on the stock. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $16.80.

Replimune Group Stock Up 3.2 %

Shares of NASDAQ:REPL opened at $11.48 on Friday. The company has a market cap of $784.31 million, a price-to-earnings ratio of -3.51 and a beta of 1.21. The firm’s 50-day simple moving average is $10.62 and its 200-day simple moving average is $8.74. The company has a quick ratio of 13.46, a current ratio of 13.46 and a debt-to-equity ratio of 0.16. Replimune Group, Inc. has a fifty-two week low of $4.92 and a fifty-two week high of $15.48.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.78) EPS for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.10. As a group, equities research analysts predict that Replimune Group, Inc. will post -3.11 earnings per share for the current year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.